Literature DB >> 35862740

Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy.

Krina Mehta1, Tingjie Guo1, Robert S Wallis2, Piet H van der Graaf1,3, J G Coen van Hasselt1.   

Abstract

Quantitative systems pharmacology (QSP) modeling of the host immune response against Mycobacterium tuberculosis can inform the rational design of host-directed therapies (HDTs). We aimed to develop a QSP framework to evaluate the effects of metformin-associated autophagy induction in combination with antibiotics. A QSP framework for autophagy was developed by extending a model for host immune response to include adenosine monophosphate-activated protein kinase (AMPK)-mTOR-autophagy signaling. This model was combined with pharmacokinetic-pharmacodynamic models for metformin and antibiotics against M. tuberculosis. We compared the model predictions to mice infection experiments and derived predictions for the pathogen- and host-associated dynamics in humans treated with metformin in combination with antibiotics. The model adequately captured the observed bacterial load dynamics in mice M. tuberculosis infection models treated with metformin. Simulations for adjunctive metformin therapy in newly diagnosed patients suggested a limited yet dose-dependent effect of metformin on reduction of the intracellular bacterial load when the overall bacterial load is low, late during antibiotic treatment. We present the first QSP framework for HDTs against M. tuberculosis, linking cellular-level autophagy effects to disease progression and adjunctive HDT treatment response. This framework may be extended to guide the design of HDTs against M. tuberculosis.

Entities:  

Keywords:  autophagy; host-directed therapy; mathematical modeling; quantitative systems pharmacology; tuberculosis

Mesh:

Substances:

Year:  2022        PMID: 35862740      PMCID: PMC9380544          DOI: 10.1128/aac.00366-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  35 in total

1.  Whole blood bactericidal activity during treatment of pulmonary tuberculosis.

Authors:  Robert S Wallis; Solange A Vinhas; John L Johnson; Fabíola C Ribeiro; Moisés Palaci; Renata L Peres; Ricardo T Sá; Reynaldo Dietze; Allan Chiunda; Kathleen Eisenach; Jerrold J Ellner
Journal:  J Infect Dis       Date:  2003-01-06       Impact factor: 5.226

Review 2.  Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.

Authors:  Tawanda Gumbo; Iñigo Angulo-Barturen; Santiago Ferrer-Bazaga
Journal:  J Infect Dis       Date:  2015-06-15       Impact factor: 5.226

3.  Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-10-01       Impact factor: 9.079

4.  IL-1β promotes antimicrobial immunity in macrophages by regulating TNFR signaling and caspase-3 activation.

Authors:  Pushpa Jayaraman; Isabel Sada-Ovalle; Tomoyasu Nishimura; Ana C Anderson; Vijay K Kuchroo; Heinz G Remold; Samuel M Behar
Journal:  J Immunol       Date:  2013-03-13       Impact factor: 5.422

Review 5.  Host-directed therapy to combat mycobacterial infections.

Authors:  Gül Kilinç; Anno Saris; Tom H M Ottenhoff; Mariëlle C Haks
Journal:  Immunol Rev       Date:  2021-02-09       Impact factor: 12.988

6.  Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.

Authors:  Nicholas R Degner; Jann-Yuan Wang; Jonathan E Golub; Petros C Karakousis
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 20.999

7.  Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages.

Authors:  Matthew Fidler; Justin J Wilkins; Richard Hooijmaijers; Teun M Post; Rik Schoemaker; Mirjam N Trame; Yuan Xiong; Wenping Wang
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-07-16

8.  Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis.

Authors:  Chandrasekaran Padmapriydarsini; Megha Mamulwar; Anant Mohan; Prema Shanmugam; N S Gomathy; Aarti Mane; Urvashi B Singh; Nathella Pavankumar; Abhijeet Kadam; Hemanth Kumar; Chandra Suresh; Devaraju Reddy; Poornaganga Devi; P M Ramesh; Lakshmanan Sekar; Shaheed Jawahar; R K Shandil; Manjula Singh; Jaykumar Menon; Randeep Guleria
Journal:  Clin Infect Dis       Date:  2022-08-31       Impact factor: 20.999

9.  The granuloma in tuberculosis: dynamics of a host-pathogen collusion.

Authors:  Stefan Ehlers; Ulrich E Schaible
Journal:  Front Immunol       Date:  2013-01-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.